Mirapexin prolonged release formulation launched

A once daily formulation of pramipexole (Mirapexin Prolonged Release) has been launched for the treatment of idiopathic Parkinson's disease.

The new preparation is available in five strengths: 0.26mg, 0.52mg, 1.05mg, 2.1mg and 3.15mg.
Treatment with Mirapexin Prolonged Release should be initiated at 0.26mg daily, increasing to a maximum of 3.15mg per day as necessary.

View Mirapexin drug record

Further information: Boehringer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...